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PURPOSE. The purpose of this review was to examine the efficacy of botulinum toxin in the
treatment of infantile esotropia and to evaluate the average response of BT and its
complication rates.
METHODS. A research was performed in the Latin American and Caribbean Literature on Health
Sciences (LILACS), MEDLINE, and Cochrane Central Register of Controlled Trial (CENTRAL).
The database was searched between December 28, 2016 and January 30, 2017. The selection
was restricted to articles published in English, Spanish, or Portuguese. There were no date
restrictions in the search.
RESULTS. Nine studies were eligible for inclusion. The grouped success rate of BT treatment in
infantile esotropia was 76% (95% confidence interval [CI]: 61%–89%). For the success rate, I2
of 94.25% was observed, indicating a high heterogeneity (P < 0.001). The complication rates
were also analyzed. The grouped consecutive exotropia (XT) rate was 1% (95% CI: 0%–2%).
The grouped ptosis rate was 27% (95% CI: 21%–33%). The grouped vertical deviation rate was
12% (95% CI: 4%–22%). The mean change of the deviation after BT injection was 30.7 (95%
CI: 37.7, 23.8), demonstrating a significant improvement in alignment.
CONCLUSIONS. Botulinum toxin injection into medial recti muscles reveals to be a safe
procedure and a valuable alternative to strabismus surgery in congenital esotropia, especially
in moderate deviations.
Keywords: botulinum toxin, strabismus, infantile esotropia
Infantile or congenital esotropia is a large angle convergentdeviation with onset prior to 6 months of age in neurolog-
ically normal children. It is usually not related to refractive
errors and often associated with other motor abnormalities,
such as inferior oblique overaction, dissociated vertical
deviation (DVD), and latent nystagmus.1,2
The prevalence of esotropia in the population is approxi-
mately 1%, while the prevalence of infantile esotropia reported
at birth is 27 per 10,000 live births.1 Children who develop
infantile esotropia begin it at approximately 4 months of age. Its
etiology is a source of controversy and remains unknown.1,3
Most investigators agree that early surgical intervention
improves both motor and sensory outcomes, even if early
surgery reoperation is common and binocular outcomes can be
poor.4,5 Although the treatment of choice for most patients
remains surgical, opinions continue to differ as to the best
approach, particularly in small and moderate angle deviations.
Alan Scott pioneered the pharmacologic treatment of
strabismus in 1980.6 Botulinum toxin (BT), which is an
exotoxin of the bacterium Clostridium botulinum, was
approved by the FDA in 1990. Botulinum toxin A is a large
protein molecule that, when injected in the muscle, remains at
the nerve terminal, inhibiting the release of acetylcholine and
resulting in muscle weakness or paralysis 3 to 5 days after the
injection. An irreversible binding occurs and the muscle
paralysis lasts approximately 8 to 12 weeks.3 The chemo-
denervated muscle lengthens and its antagonist contracts.
Sensory mechanisms may also play a role in the realignment
after treatment with BT A in some types of strabismus. The
visual axes may adopt an alignment that permits binocular
single vision; and this may persist or regress, demanding further
treatment.3,6,7 Initial doses of botulinum toxin for individual
muscles were initially suggested by Alan Scott (Table 1).8
Botulinum toxin injection in the extraocular muscles is an
alternative option that has become well established in some
cases of adult strabismus, such as sixth nerve palsy. Its use in
children is more controversial, as it requires sedation and some
complications, as ptosis, may be more frequent in this
population.3,6,7 Nevertheless, many investigators have advocat-
ed the use of botulinum toxin as a good alterative in the
treatment of infantile esotropia, as it is a less invasive procedure
than muscle surgery.
The success of BT injections in infantile esotropia seems to
be related to the age that the treatment is performed. There is
a critical age when the medial rectus muscle is more sensitive
to the chemodenervation induced by BT, allowing the
antagonist lateral rectus to regain its function. Besides,
morphologic modifications in the structure of the extraocular
muscles (i.e., tight medial recti on the forced duction test) are
apparently still deficient at early ages. It has been demonstrat-
ed that botulinum toxin affects the extraocular muscles in
infant monkeys more severely and for longer than those in
adult monkeys.9,10
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It could be assumed that early treatment allows a ‘‘self-
adjusting’’ sensorimotor mechanism to support stable binoc-
ular alignment near orthoposition, once the motor system has
been suitably modified. In fact, at early ages, the central
connections of the sensory and motor visual systems can still
be changed.
The complications reported on the use of BT include
secondary ptosis; initial consecutive exotropia (XT) lasting up
to 2 to 3 months; and the temporary effect of the BT injection
itself.8,13–18 Also, many studies show that multiple injections
may be needed to sustain the alignment effect.19 On the other
hand, the advantage is that BT is a simple treatment, in which
injections are performed under minimal anesthesia without
intubation. However, some studies show that the motor and
sensory outcomes may be significantly worse than surgery
even with multiple injections.20
What is the importance of this review?
Currently there are no guidelines about the use of BT in the
treatment of infantile esotropia. In the past decades, several
retrospective case series have been published on its use to
treat strabismus. The studies were performed in different types
of strabismus, using different doses, methods and follow-up
times. The outcomes were diverse.
The main purposes of this study were to examine the
efficacy of BT in the treatment of infantile esotropia and to
evaluate its dose response and complication rates.
METHODS
Search Methods for Identifying Studies
Research was performed in the Latin American and Caribbean
Literature on Health Sciences (LILACS); MEDLINE; and
Cochrane Central Register of Controlled Trial (CENTRAL).
The database was searched between December 28, 2016, and
January 30, 2017. The selection was restricted to articles
published in English, Spanish, or Portuguese. There were no
date restrictions in the search.
The strategies used were: botulin* toxin*; botulinum toxin;
Clostridium botulin; Botox; strabismus; esotropia; infantile
esotropia; congenital esotropia.
Study Selection
We screened the titles and abstracts from the search to
determine if the study met the inclusion criteria.
We included trials in which BT of any brand was used and
compared the results of the treatment of infantile esotropia.
Data Collection and Risk of Bias Assessment
We searched for the following elements from the studies:
1. Inclusion and exclusion criteria, presence of a group of
patients with infantile esotropia, follow-up period,
success criteria.
2. Age at which the procedure was performed, history of
previous treatment.
3. Type of BT used, dose, and number of injections.
4. Motor and sensory outcomes after a minimum follow up
of 6 months.
5. Effects.
6. Bias.
The following analyses were performed: success rate and
possible factors associated to success; association of compli-
cations with the dose of BT and complications reported at each
study; and mean variation of the deviation after BT injection.
A minimum follow-up of 6 months was required to access
the primary outcomes. Motor success was defined as
postprocedure deviation within 10 prism diopters (PD) of
orthotropia. Sensory success was defined as normal ranges of
binocular single vision.
The following adverse outcomes were considered: induced
ptosis, induced vertical deviation, and consecutive exotropia.
Eligibility Criteria
The criteria for considering studies for this review were:
studies analyzing neurologically normal patients with infantile
esotropia, minimum follow up of 6 months, botulinum toxin
injection performed in both medial recti muscles, and criteria
of success postoperative deviation within 10 PD in primary
position.
Exclusion Criteria
The criteria for excluding studies for this review were:
previous strabismus surgery in the population studied;
botulinum toxin injected in only one medial rectus muscle;
population studied including types of esotropia other than
infantile esotropia
Data Synthesis and Analysis
The heterogeneity between studies was evaluated through the
use of the I2 statistics.21 The I2 statistics varies from 0 to 100,
and the higher it is, the greater the heterogeneity observed
among the rates.
The complications (consecutive exotropia, ptosis, and
vertical deviations), and the deviation change were presented
using a random model. Meta-regression models were fitted to
identify possible sources of heterogeneity between the
estimations.
A significance level of 5% was used for all statistical tests.
Statistical analyzes were performed using statistical software
(STATA 12.0; Stata Corp., College Station, TX, USA).
RESULTS
The electronic searches identified a total of 508 titles and
abstracts, and we requested the full text of 44 studies (Table 2).
TABLE 1. Botulinum Toxin Dosage for Strabismus Treatment
Adults
Children
>12 y >12.5 kg 10–12 kg 6–9 kg <6 kg
Horizontal or vertical deviations <20 PD 1.25–2.5 U 1.25 U 1.25 U 1.25 U –
Horizontal or vertical deviations 20–50 PD 2.5–5 U 1.25–2.5 U 1.25–1.75 U 1.25 U 1 U
Persistent sixth nerve palsy of ‡1 mo duration (medial rectus) 1.25–2.5 U 1.25 U 1.25 U 1.25 U 1 U
U, units.
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We included a total of 9 studies that matched the inclusion
criteria for analysis.
Description of Studies
Details of the 9 included studies can be found in Table 3. Scott
et al.8 treated 413 children ranging in age from 2 months to 12
years with all types of strabismus. The doses of BT varied from
1 to 2.5 IU based on the degree of deviation. If a subsequent
injection was required, the dose was increased up to double
the prior dose. We selected the group of infantile esotropes
with no prior operation (61 children) for analysis. Patients
were treated at a mean age of 25 months. The preinjection
deviation was 43 PD and 66% of the patients were within 10
PD of orthotropia in the last follow up (mean 29 months). By
the end of the study, 25% of this group required surgery.
In a more recent study, de Alba Campomanes et al.11
compared BT with surgery as the primary treatment of infantile
esotropia. We analyzed only the BT group (322 children).
Injections of 5 IU of botulinum toxin (Botox; Allergan, Irvine,
CA, USA) were performed in deviations of less than 50 PD and
7.5 IU in deviations greater than 50 PD. Success rate was 45%
after a mean number of injections of 1.6. According to the
authors, the most important predictor of alignment in the BT
group was the pretreatment magnitude of deviation. In those
patients with an esotropia of 30 PD or less, the success rate of
botulinum toxin was similar to surgery. On the other hand,
stratification by preoperative deviation revealed that among
subjects with strabismus bigger than 30 PD, surgery achieved
72% success and BT 36% (risk ratio, 2.0; 95% CI, 1.5–2.7). From
the BT group, 74 (22.9%) underwent surgery for under-
correction, and four patients who were aligned in primary gaze
had surgery to correct dissociated vertical deviation or oblique
muscle overaction. No patients in this group had surgery to
correct consecutive exotropia.
McNeer et al.12 studied 76 children submitted to 2.5 IU of
botulinum toxin (Botox; Allergan, Irvine, CA, USA) trans-
conjunctival injection with the use of an electromyographic
monitor. The authors divided the patients in two groups
according to age at injection. For statistical analysis, we
considered the groups separately (groups A and B). Patients
who received the BT before 12 months of age (mean 7.8
months) had a success rate of 93%, while patients older than
12 months (mean 25.6 months) had a success rate of 86%. The
mean follow-up was 36 months.
Benabent et al.13 studied 40 children with essential infantile
esotropia. They were submitted to the injection of 7 IU of
botulinum toxin (Botox; Allergan, Dublin, Ireland) in the
medial recti without electromyographic assistance. The mean
initial deviation was 25.8 PD and 6 months after the injection it
reduced to an average of 8.5 PD (success rate 53%). Ptosis was
present in 23% of the injected eyes. It was transient and lasted
less than 3 months in all patients.
Campos et al.14 evaluated the results of BT performed under
direct visualization with an ‘‘open sky’’ technique in 60
children with essential infantile esotropia. Mean age at
injection was 6.5 months. Average follow-up was 5.2 years
and success rate was 88% after a single treatment. All patients
TABLE 2. Results of the Electronic Search
PUBMED Medline CENTRAL
Botulinum toxin AND esotropia 174 54 1
Botulinum toxin AND strabismus 508 493 1
Botulinum toxin AND esotropia
AND surgery
– 29 –
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developed a transient exotropia 1 to 2 weeks after the
procedure. A total of 20% of all the injected eyes developed
transient ptosis.
In 1994, McNeer et al.15 reported the results in 57 patients
followed for a mean time of 12 months. As the authors
analyzed two subgroups according to the age when BT
injection was performed, here we also considered the results
separately for statistical analysis. The dose of 2.5 IU of
botulinum toxin was injected guided by an electromyographic
monitor. Both subgroups (BT performed before and after 12
months of age) had 100% of success in the alignment
correction.
In another research, Scott et al.16 evaluated 356 children
treated between 2 months and 12 years. Dosages varied from 1
to 12.5 IU according to angle of deviation. We analyzed the
group treated for infantile esotropia with no previous surgery
(58 children). Approximately 2.1 injections were required to
achieve 66% of success rate.
Chen et al.17 compared the results of BT combined or not
with sodium hyaluronate. We only included in the analysis the
group in which BT was injected alone. A total of 24 cases were
treated with one injection of 2.5 to 3.75 IU of botulinum toxin
(Botox; Lanzhou Institute of Biological Products, Lanzhou,
China) without electromyography at a mean age of 35.8
months. Six months after the procedure, 37.5% of the patients
presented good alignment.
Lastly, Gursoy et al.18 performed a prospective report. They
compared the results of BT injection versus muscle surgery to
treat infantile esotropia. A total of 25 patients were submitted
to BT at a mean age of 10 months. After a mean follow-up time
of 84 months and an average of 1.4 injections, 68% of the
patients achieved successful alignment.
Statistical Analysis
Due to the substantial heterogeneity observed in the results,
the success rate, the complications, and the deviation change
were presented using a random model. Subsequently, meta-
regression models were fitted to identify possible sources of
heterogeneity between the estimations.
The grouped success rate of botulinum toxin treatment in
infantile esotropia was 76% (95% confidence interval [CI]:
61%–89%; Fig. 1). For the success rate, I2 of 94.25% was
observed, indicating a high heterogeneity (P < 0.001). Studies
1, 7, and 9 presented similar rates (between 66% and 68%), as
did studies 3B and 5 (86% and 87%, respectively). On the other
hand, study 8 had the lowest success rate (38%) and study 6 (A
and B), 100% of success. We attempted to identify the possible
causes of heterogeneity by considering the means of the age,
initial deviation, mean number of injections, follow-up time,
and sample size via meta-regression. Univariate and multivar-
iate models were adjusted and are presented on Table 4. There
was no association between the success rates and the study
variables.
Meta-regressions were adjusted for the seven studies that
performed the injections with the same dosage of BT (3A, 3B,
4, 5, 6A, 6B, and 9). Due to the number of studies, for the
multivariate model we considered the significant predictor
variables at 20%.
As shown in Table 5, only the dose remained significant in
the multivariate model (P¼ 0.025). Thus, excluding the mean
number of injections of the model, we consider the univariate
model only with the dose (P ¼ 0.005). Therefore, the higher
the dose of BT injected, the lower the success rate; every 1 IU
increased in the mean dose there was a reduction of 0.10% in
the success rate.
FIGURE 1. Grouped success rate.
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When correlating the technique used for BT injections and
success rates, the injections guided by electromyography
revealed higher success rates than the transconjunctival
injections with no electromyography (EMG; P¼ 0.006). When
EMG and direct visualization injection were compared, there
was no statistic difference (P ¼ 0.89).
The complication rates were also analyzed. The occurrence
of permanent consecutive XT, transient ptosis, and vertical
deviation were considered complications. For meta-regres-
sions, age and dose were considered predictors, when
possible.
According to Figure 2, only five studies contributed to the
analysis of consecutive XT. The grouped consecutive rate of XT
was 1% (95% CI: 0%–2%). For this analysis, the I2 was 0% (P¼
0.490) indicating homogeneity among the estimates. In four of
the five studies, no cases of consecutive XT were reported and
one study presented a rate of only 3%. Supporting this, there
was no association between the consecutive XT rate and age (P
¼0.435) via meta-regression. It was not possible to evaluate the
dose-effect as the four studies using a single dose (5, 6A, 6B,
and 9) had no consecutive XT cases.
Seven studies contributed to the analysis of the occurrence
of ptosis. The grouped ptosis rate was 27% (95% CI: 21%–33%;
Fig. 3). The value of I2 was 20% (P¼0.280); therefore, the rates
of ptosis were not considered heterogeneous. Only the 6A
study presented a rate of ptosis higher than 40%, the other
studies presented rates ranging from 17% to 32%. By the meta-
regression analysis, there was no association between the rate
of ptosis and age (P¼ 0.654), as well as the dose of BT injected
(P ¼ 0.581).
When analyzing the occurrence of vertical deviation, the
grouped rate was 12% (95% CI: 4%–22%; Fig. 4). For this
analysis, I2 was 68.1% (P ¼ 0.020), showing heterogeneity.
Study 8 had no case of this complication, differently from the
others that presented rates above 15%. There was no
association between the rate of vertical deviation and age (P
¼ 0.069) via meta-regression. It was not possible to assess the
effect of the dose as only four studies presented the single dose
regardless the dose being smaller or larger.
The mean change of the deviation after BT injection was
30.7 (95% CI: 37.7, 23.8), demonstrating a significant
improvement in alignment (Fig. 5). For this analysis, I2 was
88.1% (P < 0.001) denoting that the mean deviation change in
the studies was heterogeneous. Adjusting for a meta-regression
model and considering age as a predictor variable, it was
significant (P¼0.020), indicating that the older the child at the
time of the procedure, the greater the deviation/increase of
0.65 diopters (95% CI: 0.19, 1.11) at every 1-year increase in
mean age, reducing the delta in the deviation. It was not
possible to establish dose effect information.
DISCUSSION
Surgical success rates for infantile esotropia have been
reported by Scott et al.22 (65%); von Noorden et al.23 (66%);
and Issaho et al.24 (59%). Currently most strabismus specialists
prefer surgery to other treatments due to the more predictable
results in the alignment.
Scott6 first described the use of botulinum toxin in the
treatment of strabismus in 1980 and afterward several authors
also reported their outcomes. However, it remains unclear how
effective and predictable the BT is in comparison to other
options to treat strabismus.
Nine studies in which BT injection was performed to treat
infantile esotropia were included in this analysis. Two reports
were subdivided for analysis12,15 since the results were
provided separately according to age.
All the authors used botulinum toxin, except for Scott et
al.8,16 who did not specify the type of BT injected. Additionally,
some authors used the transconjunctival technique with EMG
assistance in the procedures.8,12,15,16 Others opted for no EMG
assistance.11,13,17,18 Campos et al.14 performed the injections
under direct visualization of the muscle.
TABLE 4. Meta-Regression Results for Success Rate
Meta-Regression
Univariate Multivariate
Coefficient (95% CI) P Value Coefficient (95% CI) P Value
Mean age 0.0115 (0.0267; 0.0038) 0.124 0.0141 (0.0319; 0.0037) 0.098
Preop deviation 0.0010 (0.0274; 0.0293) 0.940 0.0204 (0.0588; 0.0180) 0.230
Mean number of injections 0.1613 (0.1883; 0.5108) 0.324 0.3061 (0.1660; 0.7782) 0.156
Mean follow up 0.0016 (0.0053; 0.0085) 0.614 0.0002 (0.0076; 0.008) 0.953
Number of patients 0.0011 (0.0028; 0.0005) 0.160 0.0011 (0.0027; 0.0006) 0.156
N ¼ 11.
TABLE 5. Meta-Regression Results for Success Rate Considering a Pattern Dose of Botulinum Toxin
Meta-Regression
Univariate Multivariate
Coefficient (95% CI) P Value Coefficient (95% CI) P Value
Mean age 0.0034 (0.0250; 0.0182) 0.700 – –
Mean preop deviation 0.0120 (0.0175; 0.0415) 0.343 – –
Mean number of injections 0.2635 (0.0821; 0.6091) 0.107 0.0534 (0.1735; 0.2803) 0.549
Mean follow up 0.0011 (0.0079; 0.0058) 0.706 – –
Patients, n 0.0010 (0.0173; 0.0153) 0.886 – –
Dose 0.1019 (0.1558; 0.048) 0.005 0.0914 (0.1644; 0.0184) 0.025
N ¼ 7.
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FIGURE 2. Grouped rate of consecutive exotropia.
FIGURE 3. Grouped ptosis rate.
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FIGURE 4. Grouped vertical deviation rate.
FIGURE 5. Grouped variation of the deviation.
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We were able to report the primary outcome of improved
ocular alignment by a reduction in the mean deviation in all
nine studies. Mean preinjection deviation was 38 PD, while
mean postinjection deviation was 6.25 PD. The average
number of injections was 1.4. The grouped success rate of
BT injection was 76%, but we did observe a high heterogeneity
in the studies (I2 statistics: 94.25%). It was not possible to
evaluate the dose response of BT across a range of different
doses used in some of the studies.
An interesting result was the inverse association between
the dose of BT and the success rate. We observed that the
higher the dose of BT injected, the lower the success rate—
every 1 IU increased in the mean dose there was a reduction of
0.1% in the success rate. Probably this is due to the tendency to
use higher doses of BT in bigger angles of deviation. Alba
Campomanes et al.11 concluded that BT was most effective for
esotropia ranging from 30 to 35 PD, with a success compared
to surgery. Success with BT injection when deviation was
lower than 30 PD was 51%, while the rate was 39% if deviation
was greater than 30 PD. The magnitude of deviation predicted
motor outcome when strabismus was treated with BT instead
of surgery.
Scott et al.8 and de Alba Campomanes et al.11 also analyzed
the success rates considering initial angle of deviation (smaller
or bigger than 30 PD). They showed better rates in smaller
deviations (73% and 59%, respectively) than in bigger
esotropias (54% and 36%, respectively).
The average change of the deviation after BT injection was
30.7, revealing a significant improvement in alignment after
the intervention, although the mean deviation change in the
studies was heterogeneous. This supports the indication of BT
injection as a good alternative to treat moderate esotropia
(until 30–35 PD of deviation).
Furthermore, the risk of experiencing anesthesia-related
complications in a healthy infant is negligible, but this should
still be considered. In addition to the procedural simplicity of
botulinum toxin injection, performing it under minimal
anesthesia without intubation in a baby is another advan-
tage.25,26
When evaluating the occurrence of complications, the
grouped consecutive rate of XT was very low (1%). Hypo-
correction is much more frequent than hypercorrection. The
overall ptosis rate was 27% with low heterogeneity and vertical
deviation rate was 12% with high heterogeneity between
groups.
Other less frequent adverse outcomes cited include
subconjunctival hemorrhage and diplopia. Inferior oblique
overaction and DVD were also observed, but they are naturally
associated with infantile esotropia, and not a consequence of
the BT injection. Issaho et al.24 reported frequencies of 38% of
inferior oblique overaction and 18% of DVD in a large group of
children with infantile esotropia submitted to bilateral medial
recti recession. Serious complications such as globe perfora-
tion did not occur in any of the studies.
Only two authors attempted to analyze the binocular vision.
Scott et al.8 revealed that of the patients that could be tested
for binocularity, several had good motor fusion, but only one
third had full stereopsis. Gursoy et al.18 compared the results of
BT injection versus muscle surgery. Binocular vision with
Bagolini-striated glasses was detected in 86% of the reliable
responders in the BT and 78% in the surgery group. Gross
stereopsis was demonstrable in 10 of 15 patients in the
botulinum group and 9 of 13 in the surgery group (odds ratio¼
3.6, P ¼ 0.46). Two patients in the botulinum group achieved
stereoacuity of 40 arc seconds.
Our results elucidate many questions currently experienced
on the use of botulinum toxin to treat infantile esotropia.
However, most of published literature consists of retrospective
studies, case reviews or cohort studies. Although these provide
very useful descriptive information, in order to improve the
evidence base for the use of botulinum toxin as an
independent management alternative, there is a strong
necessity for good quality randomized trials to be performed.
Standardization is very important, considering the types of
botulinum toxin available and especially the different dosages
used as these features are not quite comparable. The evaluation
of binocular vision is also an important factor to be considered
in future trials.
CONCLUSIONS
Botulinum toxin injection into medial recti muscles reveals to
be a safe procedure and offers a valuable alternative to
strabismus surgery in congenital esotropia, especially in
moderate deviations.
Randomized clinical trials are necessary to consolidate the
effective use of botulinum toxin as an independent treatment
modality.
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